Report
Piramal Pharma cuts exposure to Chinese raw materials
Bloomberg reports the Indian contract drug manufacturer made the move to reduce concentration risk.
TLDR
Piramal Pharma has cut its exposure to Chinese raw materials in a bid to reduce concentration risk, Bloomberg reports.
Combined views
—
1 Source, first seen ago
— likes— comments— saves— reposts